Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: In two placebo‐controlled 30‐week trials, treatment with exenatide reduced HbA 1c and body weight in patients with type 2 diabetes in the context of sulphonylurea (SU) or SU plus metformin (MET) as background treatment. This analysis examines the effects of 82 weeks of exenatide treatment for participants in these earlier 30‐week trials. Methods: Data were pooled from the two pivotal trials of exenatide added to SU or SU plus MET. Both 30‐week, placebo‐controlled trials of 5 µg or 10 µg exenatide b.i.d. were followed by 52‐week open‐label, uncontrolled extension studies in which all participants received 10 µg exenatide b.i.d. and continued prior oral therapies. This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 ± 10 y, weight 99 ± 21 kg, BMI 34 ± 6 kg/m 2, HbA 1c 8.4 ± 1.0% [mean ± SD]). Results: Reduction in HbA 1c from baseline to week 30 (−0.8 ± 0.1% and −1.0 ± 0.1% for 5 µg b.i.d. and 10 µg b.i.d., respectively [mean ± SE]) was sustained up to week 82 (−1.0 ± 0.1%). Of 207 patients with baseline HbA 1c > 7%, 44% achieved HbA 1c ≤ 7% at week 82. Reduction of body weight from baseline to week 30 (−1.4 ± 0.3 kg and −2.1 ± 0.3 kg for 5 µg b.i.d. and 10 µg b.i.d., respectively) was progressive up to week 82 (−4.0 ± 0.3 kg). The most frequent adverse events were nausea and hypoglycaemia, both generally mild to moderate in intensity. Conclusions: Exenatide added to maximally effective doses of SU or SU plus MET resulted in a sustained reduction in HbA 1c and a progressive reduction in weight over $\def\qdr#1#2{\begingroup\hbox{\raise0.3em\hbox{$\scriptstyle #1$}$\!{/}\!$\lower0.2em\hbox{$\scriptstyle #2$}}\endgroup}1\qdr{1}{2}$ years. Copyright © 2006 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408 · cited 1×
“The main inclusion criteria for patients in both the initial placebo-controlled trials were age between 16 to 75 years and type 2 diabetes treated for at least 3 months prior to screening with the maximally effective dose of an SU alone [12,13] or combined with ≥1500 mg/day of MET.”
BackgroundCombination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300 · cited 2×
“are likely to gain weight and have an increased risk of hypoglycaemia [2,3,6].”
BackgroundResultRatner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217 · cited 1×
“Data for subjects from the third pivotal trial, in which exenatide was used with MET alone, are reported elsewhere [11].”
BackgroundSelf-citation
Research works printed but not linked: 13
- 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
- 1998, Lancet, 352, 1557
- 10.1111/j.1600-051X.1988.tb01003.x · DOI · Paper page
- 10.1016/S0140-6736(05)77963-0 · DOI
- 10.1002/dmrr.478 · DOI · Paper page
- 10.2165/00024677-200302010-00004 · DOI
- 10.1016/j.regpep.2003.10.028 · DOI · Paper page
- 10.1007/BF00606420 · DOI
- 10.2337/diacare.17.10.1100 · DOI · Paper page
- 10.1016/S0168-8227(99)00002-9 · DOI · Paper page
- Campbell IW, 1994, One year comparative trial of metformin and glipizide in type 2 diabetes mellitus, Diabetes Metab, 20, 394
- 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
- 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationHandelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Asche, C., LaFleur, J., & Conner, C. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.019 · Cited by 420
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373
“Exenatide (exendin-4) is a currently licensed DPP-IV resistant GLP-1R agonist that has enjoyed success in producing improved glycaemic control and promoting weight loss when administered subcutaneously to overweight patients with type 2 diabetes.(71,72) Long acting analogues of GLP-1 such as liraglutide are also licen…”
BackgroundMetformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
The Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults
Franz, M. J., Powers, M. A., Leontos, C., Holzmeister, L. A., Kulkarni, K., Monk, A., Wedel, N., & Gradwell, E. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.09.014 · Cited by 306
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
“[32, 33] Finally, 8 were open label extension studies.[34-41] This left 32 trials included in our review (Figure 1 and Table 1).”
BackgroundGlucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Buysschaert, M., Preumont, V., Oriot, P. R., Paris, I., Ponchon, M., Scarnière, D., & Selvais, P. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.009 · Cited by 68
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Metadata
- Authors
- Riddle, M. C., Henry, R. R., Poon, T. H., Zhang, B., Mac, S. M., Holcombe, J. H., Kim, D. D., & Maggs, D. G.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2006-04-24
- Volume
- 22
- Issue
- 6
- Pages
- 483-491
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1972204120
- Cited by
- 126
- References
- 8
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.